Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This pharmacovigilance study found an increased association of suicidality and psychological adverse events with finasteride use, especially among younger patients using it for alopecia.

This study found that the developed Finasteride-loaded SMEDDS improved the relative bioavailability of the drug compared to a commercial tablet, offering a promising oral delivery system for glucosteroid analogs.

This review summarizes existing research on the use of finasteride for treating androgenetic alopecia in men, reporting its effectiveness at 1 mg/day and a strong safety profile, but presents no new findings.

This study found that both finasteride and flutamide effectively reduced hirsutism in women with polycystic ovary syndrome, decreasing the Ferriman-Gallwey score and hair diameter without significant side effects.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

This study found that finasteride increased fetal arousal activity in late gestation sheep by suppressing pregnane steroid synthesis, suggesting reduced GABAA receptor-mediated inhibition.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.

Finasteride reduces alcohol withdrawal effects, especially in female mice.

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.

In this study, a topical formulation with compounds from the monoterpenoid family significantly improved hair growth indicators like anagen:telogen ratio, hair fall, and visual hair density in men and women with pattern hair loss.

This study reported that 6 months of finasteride treatment significantly improved idiopathic hirsutism in women, with benefits persisting 6 months post-treatment and no adverse reactions observed.

This study found that testosterone treatment in older hypogonadal men caused minor improvements in depressive symptoms and visuospatial memory, but overall, major cognitive benefits were not observed.

This study presents a validated HPTLC method for simultaneously determining five BPH drugs, showing high sensitivity and selectivity for potential use in quality-control analysis.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This study reported that prenatal exposure to dihydrotestosterone altered long-term androgen metabolism in juvenile male rats, suggesting different regulatory mechanisms for 5a-reductase in hypothalamic versus pituitary tissues.

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This study identified new potential targets and indications for several marketed drugs using in silico profiling, suggesting opportunities for drug repositioning.

This study found that Transcutol P significantly enhanced the skin penetration of Finasteride in vitro, while cationic and anionic surfactants did not show such effects.

This study found that the dimethyl-β-cyclodextrin inclusion system significantly improved the solubility and bioavailability of finasteride compared to the drug alone, enhancing its absorption rate.

This study found that capped mesoporous silica nanoparticles conjugated with antibodies selectively released a dye when exposed to finasteride, with low detection limits and stable performance even after storage.

Finasteride blocks progesterone's effect on absence seizures in rats.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study found that finasteride alone is highly effective in preventing Candida albicans urinary biofilms and shows synergistic activity with fluconazole in vitro, suggesting potential for further clinical investigation.

Method quickly measures finasteride concentration in capsules.

In this laboratory study with rats, treatment with finasteride reduced dihydrotestosterone levels and fertility parameters, with a 30-day recovery period proving insufficient to fully restore sperm function and fertility.

Accurate method measures finasteride levels in human plasma using gas chromatography-mass spectrometry.

This study found that the pharmacological inhibition of 5-α reductases with finasteride and dutasteride can reduce neurosteroid synthesis in glioblastoma-derived cell lines, potentially impacting GBM survival.